Table 1 The role of NSUNs in different tumors.
From: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
NSUNs | Cancer type | Expression | Prognosis | Target genes or pathways | Biological function | Source of difference | References |
|---|---|---|---|---|---|---|---|
NSUN1 | HGSOC | Up-regulated | Unfavorable | RAPGEF4 | Promote cell proliferation, migration, and invasion. | GSE10971, HGSOC patient tissue and TCGA | [126] |
NSUN2 | PC | Up-regulated | Unfavorable | TIAM2 | Promote cell proliferation, migration, and invasion. | TCGA and GTEx GSE62452 PC patient tissues | [86] |
GC | Up-regulated | Unfavorable | NTN1 | Promotes the migration, invasion, and NI potential. | GC patient tissues | [73] | |
GC | Up-regulated | Unfavorable | FOXC2 | Promote cell proliferation, migration, and invasion. | GC patient tissues | [74] | |
GC | Up-regulated | Unfavorable | P57 | Promote cell proliferation. | TCGA and GC patient tissues | [89] | |
GC | Up-regulated | Unfavorable | NR 033928 | Promote the expression of GLS and GC proliferation. | TCGA and GC patient tissues | [96] | |
CC | Up-regulated | Unfavorable | KRT13 | Promote cancer invasion and migration. | GSE17025 and GSE106191, GSE12470 and GSE66957, GSE138080 and GSE36514, UALCAN website, oncomine, cBioPortal, CC patient tissues | [32] | |
CC | Up-regulated | Unfavorable | LRRC8A | Promote tumor growth and metastasis. | GSE63514, GSE52904, Oncomine CC patient tissues | [111] | |
BC | Up-regulated | Unfavorable | HGH1 | Promote tumor growth and migration. | TCGA and BC patient tissues | [33] | |
Pca | Up-regulated | Unfavorable | AR | Activates positive feedback loop to promote prostate cancer. | TCGA High-risk PCa patients tissues | [31] | |
ESCC | Up-regulated | Unfavorable | NMR (ERK signaling) | Promote tumor cell migration and invasion, inhibit cisplatin-induced apoptosis. | / | [59] | |
ESCC | Up-regulated | Unfavorable | GRB2 | Promote cell proliferation. | ESCC patient tissues and GSE53625 | [68] | |
RB | Up-regulated | Unfavorable | PFAS | RB growth and aggressiveness. | RB patient tissues and GSE111168 | [66] | |
EC | Up-regulated | Unfavorable | SLC7A11 | Increase lipid peroxidation and ferroptosis, promote tumor growth. | EC patient tissues, TCGA and CPTAC | [80] | |
UCB | Up-regulated | Unfavorable | RABL6 and TK1 | Enhances proliferation and invasion. | UCB patient tissues and TCGA | [97] | |
CRC | Up-regulated | Unfavorable | SKIL | Promoted CRC malignancy. | TCGA, GSE20916, GSE33113, GSE8671 and CRC patient tissues | [27] | |
CRC | Up-regulated | Unfavorable | ENO1 | Promote reprogramming of glucose metabolism. | TCGA and CRC patient tissues | [83] | |
OV | Up-regulated | Unfavorable | E2F1 | Promoted malignancy. | TCGA, GSE19071, GSE18520, GSE27651and OV patient tissues | [69] | |
AML | Up-regulated | Unfavorable | PHGDH, SHMT2 | Affect serine metabolism. | TCGA, BloodSpot database and AML patients tissues | [125] | |
HCC | Up-regulated | Unfavorable | H19 | Promote the proliferation, migration, and invasion. | HCC cell lines | [58] | |
NSCLC | Up-regulated | Unfavorable | NRF2 | Increases NSCLC ferroptosis-resistance capacity.Promote cell proliferation. | TCGA,GSE33532, GSE31210 and NSCLC tumor tissues | [113] | |
NSCLC | Up-regulated | Unfavorable | QSOX1 | Promotes gefitinib resistance. | NSCLC patient tissues | [60] | |
CCA | Up-regulated | Unfavorable | NKILA | Enhances proliferation and invasion. | TCGA CCA patient tissues | [91] | |
OS | Up-regulated | Unfavorable | FABP5 | Promote fatty acid metabolism. | GSE126209, GSE99671 and OS patient tissues | [124] | |
GBM | Up-regulated | Unfavorable | LINC00324 | Promote cell proliferation, migration and angiogenesis. | UALCAN | [93] | |
HCC(HBV) | Up-regulated | Unfavorable | HBV | Regulates HBV infection and replication. | / | [90] | |
ccRCC | Up-regulated | Unfavorable | NEO1 | Promote glycolysis and histone lactylation. | / | [122] | |
GC | Up-regulated | Unfavorable | ATG9A | Promotes 5-Fluorouracil resistance. | / | [132] | |
HCC | Up-regulated | Unfavorable | SOAT2 | Promote immune evasion. | GSE25599, GSE105130,GSE112705,GSE135631,GSE164359,GSE202069,GSE202853,GSE214846, GSE216613 and HCC patient tissues | [138] | |
OS | Up-regulated | Unfavorable | LINC01082 | Promote cell proliferation, migration. | GEPIA and OS patient tissue | [92] | |
HCC | Up-regulated | Unfavorable | MALAT1 | Promotes sorafenib resistance. | HCC patient tissues | [95] | |
NSUN3 | HNSCC | Up-regulated | Unfavorable | tRNA-C34 | Enhances mitochondrial translation rates and OXPHOS. | HNSCC patient tissues | [16] |
NSUN4 | CRC | Up-regulated | Unfavorable | NXPH4 | Promote the proliferation and growth. | TCGA, GSE37182, GSE83889 and CRC patient tissues | [107] |
GBM | Up-regulated | Unfavorable | CDC42 | Promote cell proliferation. | UCSC-XENA and GBM patient tissues | [87] | |
NSUN5 | PCa | Up-regulated | Unfavorable | ACC1 | Promote cell proliferation. | TCGA and PCa patient tissues | [85] |
HCC | Up-regulated | Unfavorable | Promote the proliferation and migration. | TCGA and HCC patient tissues | [103] | ||
COAD | Down-regulated | Favorable | GPX4 (cGAS-STING signaling) | Regulates cancer immunotherapy. | TCGA and GSE17538 | [123] | |
GBM | Up-regulated | Unfavorable | 28S rRNA | Promote overall protein translation and synthesis. | TCGA and GBM patient tissues | [102] | |
NSUN6 | CC | Up-regulated | Unfavorable | NDRG1 | Promotes radioresistance. | CC patient tissues | [135] |
ESCC | Down-regulated | Favorable | CDH1 | Inhibit proliferation, migration, and invasion. | TCGA and ESCC patient tissues | [104] | |
LUNG | Down-regulated | Favorable | NM23-H1 | Inhibit proliferation and invasion and EMT. | TCGA | [62] | |
OS | Up-regulated | Unfavorable | EEF1A2 (Akt/mTOR signaling) | Promote proliferation, migration, and invasion. | GSE126209 | [63] | |
NSUN7 | HCC | Down-regulated | Favorable | CCDC9B | Inhibit the poor prognosis of tumors. | TCGA | [49] |
